spot_imgspot_img

Update on first in human trial for Geographic Atrophy

Press Release/Jan 13, 2025 — We are delighted to announce interim results for our first in human trial for Geographic Atrophy secondary to Dry AMD.

1. Eyecyte-RPE was well tolerated across the first two doses with no serious adverse events (SAEs) and minimal Treatment Emergent Adverse Events (TEAEs).
2. Five out of Six patients had a improvement in vision (3-31 letters). At this time, improvement has been sustained at five months for the first two enrolled patients.
3. Noticeable decrease in RPE defect area and Photoreceptor defect area was observed in the injected eye vs. the uninjected eye.
4. Structural changes in OCT observed at the area of injection corroborated the functional improvements.

The excellent safety profile, along with promising signs of efficacy, will be further explored in our phase two study. Taken together, this data represents a large and critical inflection point for Eyestem in bringing this therapy to patients who need it the most !

Source: Linkedin

Website: https://eyestem.com/

Get in Touch

LEAVE A REPLY

Please enter your comment!
Please enter your name here

spot_imgspot_img

Related Articles

spot_img

Get in Touch

588FansLike
520FollowersFollow
4,100FollowersFollow
780SubscribersSubscribe

Latest Posts